Lack of Efficacy in Veterinary Pharmacovigilance: A Failure That Is Also a Report

In veterinary pharmacovigilance, failure to work is not just a quality complaint. When a medicine does not deliver the expected effect despite correct use, it is a suspected adverse event, and for antimicrobials, vaccines and parasiticides it may point to a public health or animal health problem.

Why it is in scope

The Union Pharmacovigilance Database is the central record of suspected adverse events for veterinary medicines. Guidance from national authorities such as Ireland’s HPRA lists lack of efficacy among the categories holders must report to it, alongside harmful reactions in animals and humans, environmental incidents and residues above legal limits.

Why it matters

  • Antimicrobials. A pattern of treatment failures may suggest emerging resistance, which has implications beyond one product.
  • Vaccines. Breakthrough disease in vaccinated animals can indicate a batch issue, an antigen mismatch with circulating strains or a handling problem.
  • Parasiticides. Reduced effect can be a signal of resistance developing in the target parasite.

Getting the case right

Lack of efficacy is difficult to assess because many things can explain it. A sound case record asks for:

  • the product, batch, dose, route and duration actually used;
  • the species, age, production system and the diagnosis, ideally with laboratory confirmation;
  • storage and administration conditions;
  • concurrent treatments and disease management factors.

Linking to quality and signals

Complaints that reach the quality team and cases that reach the pharmacovigilance team must be connected. A cluster of lack of efficacy reports for one batch is a quality investigation as well as a safety matter. Under the VGVP signal management approach, such clusters should also be visible in the annual detection analysis and, where they point to a change in the benefit-risk balance, escalate on the stated timelines.

Practical steps

  • Define lack of efficacy explicitly in intake procedures and training.
  • Create a joint triage between quality and pharmacovigilance for product complaints.
  • Ensure follow-up questions are standard, and record when the reporter cannot answer.

Closing the loop

The value of efficacy reporting is realised only when the information is used. Trend reports should be shared regularly between quality, pharmacovigilance and regulatory teams. If a pattern emerges, the next step may be a batch investigation, a field study, a change to the dosing wording or a notification to the authorities under the signal timelines. Recording the reasoning for each decision protects the company when the pattern is later reviewed.

  • Hold a regular joint quality and pharmacovigilance review.
  • Track repeat reporters and regions.
  • Document why each cluster was or was not escalated.

How PQRA helps

PQRA can review the interface between your complaint handling and pharmacovigilance procedures, design follow-up questionnaires by species and product type and strengthen the signal detection approach for lack of efficacy.

Questions about this topic? Contact PQRA to discuss your veterinary portfolio.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *